NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, Sept. 2,...

Newmark Closes Acquisition of Altus Group's Development Advisory Business

Newmark Closes Acquisition of Altus Group's Development Advisory Business

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or the "Company"), a leading commercial real estate advisor and service provider to large institutional investors, global corporations and other owners and...

Laifen Closes the Loop on the Beauty Routine with Three New Innovations Completing Its At-Home Beauty Ecosystem

Laifen Closes the Loop on the Beauty Routine with Three New Innovations Completing Its At-Home Beauty Ecosystem

Introducing the Swift 4 High-Speed Hair Dryer, AutoCurl Curling Iron and Glowy Vanity Mirror to Complete the Hair-to-Beauty Ritual NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Laifen, the global personal care technology brand known for redefining the...

Cherubic Ventures Closes $68.88 Million Fund VI as AUM Surpasses $500 Million

Cherubic Ventures Closes $68.88 Million Fund VI as AUM Surpasses $500 Million

Early Investment Sudo AI Valued at Nearly $2B TAIPEI, Sept. 1, 2026 /PRNewswire/ -- Cherubic Ventures today announced the close of its sixth fund (Fund VI) at $68.88 million. The fund size reflects the auspicious meaning of the number eight in East...

Beyang Closes Oversubscribed $30 Million Series A Financing

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug....

PCG Global Closes Pre-Series A to Tap into Oceania's Accelerating Renewable Capacity Expansion

PCG Global Closes Pre-Series A to Tap into Oceania's Accelerating Renewable Capacity Expansion

GUANGZHOU, China and SINGAPORE, Aug. 4, 2026 /PRNewswire/ -- PCG Global, a clean energy platform focused on renewable energy infrastructure, has announced the closing of its Pre-Series A financing round, led by GenZero, a wholly owned Temasek...

PCG Global Closes Pre-Series A to Capture Southeast Asia's Fast-Growing Power Demand

PCG Global Closes Pre-Series A to Capture Southeast Asia's Fast-Growing Power Demand

GUANGZHOU, China and SINGAPORE, Aug. 4, 2026 /PRNewswire/ -- PCG Global, a clean energy platform focused on renewable energy infrastructure, has announced the closing of its Pre-Series A financing round, led by GenZero, a wholly owned Temasek...

Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026...

Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors

Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte....

Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases

Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases

BIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed...

  • 1
  • 2
  • 3
  • menu
    menu